Cart
sales@molnova.com
Home -
Products -
MAPK/ERK Signaling -
p38 MAPK -
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate
CAS No. 517870-17-6
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate( —— )
Catalog No. M24490 CAS No. 517870-17-6
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 51 | In Stock |
|
| 50MG | 75 | In Stock |
|
| 100MG | 112 | In Stock |
|
| 200MG | 168 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namemethyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate
-
NoteResearch use only, not for human use.
-
Brief Descriptionmethyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
-
Descriptionmethyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorMAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number517870-17-6
-
Formula Weight263.25
-
Molecular FormulaC13H13NO5
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC1=C(C=C(C=C1)C2=CC(=NO2)C(=O)OC)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
p38α inhibitor 3
p38α inhibitor 3 is a inhibitor of the mitogen-activated protein kinase p38α that can block the effectiveness of myoblast differentiation.
-
CC-99677
CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
